Core Viewpoint - The article discusses the second round of inquiry from the Beijing Stock Exchange regarding the IPO application of China Academy of Sciences Shenyang Instrument Co., Ltd. (referred to as "the company"), focusing on market competition, sustainability of performance growth, and inventory risks associated with its unique "backup pump" business model [2][3][4][6]. Group 1: Market Competition - The inquiry emphasizes the challenges the company faces in a competitive market, particularly against competitors like Ebara and Kashi yama, who provide vacuum equipment for the integrated circuit sector [3]. - The company’s products still show slight gaps in reliability and stability compared to international leaders, particularly in advanced process technology accumulation [3]. - The exchange requires the company to explain the technology iteration cycles of its main competitors and analyze its competitive strategies in the integrated circuit field [3]. Group 2: Sustainability of Performance Growth - The company's revenue from the photovoltaic sector has seen a dramatic decline, raising doubts about the sustainability of its performance growth [4]. - Revenue from dry vacuum pumps in the photovoltaic sector dropped from a peak of 176 million yuan in 2023 to just 302,700 yuan in the first half of 2025, indicating a cliff-like drop [4]. - The company’s gross margin in the photovoltaic sector is lower than that of similar products, and the performance of major clients in this sector is continuously declining [5]. Group 3: Inventory Risks and Backup Pump Business Model - The inquiry highlights the inventory risks associated with the company's backup pump business model, where backup pumps are provided to clients without separate charges, leading to a significant increase in inventory from 139 million yuan to 410 million yuan [6]. - The rising inventory levels are accompanied by a declining inventory turnover rate, raising concerns about the commercial substance of this model and its implications for future orders [6]. - Financial data shows that while revenue increased from 698 million yuan to 1.082 billion yuan from 2022 to 2024, net profit saw a stark decline of 67.8% in 2024, indicating volatility in profitability [6]. Group 4: Fundraising and Financial Health - The company plans to raise 825.48 million yuan, with cash reserves of 594.84 million yuan as of June 2025, prompting the exchange to request details on the planned use of funds and expected cash inflows post-IPO [7]. - The company has highlighted risks associated with fluctuations in the stock prices of its holdings in listed companies, which could significantly impact its financial performance [8].

Core Viewpoint - JingDong Industrials (JDi), a subsidiary of JD.com, is planning an initial public offering (IPO) in Hong Kong, targeting up to $500 million, with pricing expected on December 8 and listing on December 11 [1][2]. Company Overview - JDi is engaged in industrial supply chain services and was valued at approximately $6.7 billion in its pre-IPO round in 2023 [4][5]. - JD.com holds about 79% of JDi after spinning it off in 2023 [2]. IPO Details - The IPO size may be adjusted based on initial investor interest, indicating potential for downsizing [2][4]. - JDi received approval from China's securities watchdog in September, following over two years of planning [5]. Market Context - The IPO occurs amid volatility in U.S. markets, which has negatively impacted recent listings in Hong Kong, leading to increased caution among investors [3]. - Hong Kong has seen a significant increase in new listings, totaling around $32 billion as of November 17, up over 200% year-on-year [4]. Financial Performance - In the first half of 2025, JDi reported a revenue increase of 18.9% year-on-year, reaching 10.3 billion yuan (approximately $1.4 billion) [5]. Sponsorship - The IPO is being jointly sponsored by Bank of America, Goldman Sachs, Haitong International Securities, and UBS [6].

Group 1 - The core viewpoint of the article highlights the ongoing high IPO approval rate in China's A-share market, particularly on the Sci-Tech Innovation Board and the Growth Enterprise Market, with a weekly IPO approval rate exceeding 90% [3][9][13] - Last week, 11 companies were reviewed for IPO, with 10 successfully approved, maintaining a high approval rate [3][9] - The surge in IPO applications, with 90 companies submitting applications last week, is attributed to the expiration of financial data validity and the customary rush by sponsors before the end of June [6][13] Group 2 - Notable companies that passed the IPO review include BeiGene, which aims to raise 20 billion yuan, and Joyy Technology, with significant market presence in the U.S. and Hong Kong [7][9] - The only company that was denied IPO approval last week was Kengfeng Seed Industry, which faced scrutiny due to a nearly 70% decline in net profit from 2018 to 2020 [9][13] - The article also mentions that 10 companies had their IPO reviews suspended, marking the highest number since early April, with specific concerns raised about the technological attributes and internal controls of some companies [14][15] Group 3 - This week, 12 companies are scheduled for IPO review, collectively aiming to raise over 110 billion yuan, with China National Railway Group's subsidiary, Zhongtie Special Cargo, seeking to raise 5 billion yuan [16][18] - The article notes that 259 companies have completed IPOs this year, raising over 238 billion yuan, indicating a robust IPO market [24][26] - The leading underwriter for the year is CITIC Securities, having sponsored 28 companies, reflecting a significant concentration in the underwriting market [26]

Bankers’ forecasts of an upcoming revival in European IPOs haven’t always stood the test of time. But next year, they say, really might be different https://t.co/rqImiTsDcE ...

Group 1: Company IPOs - A total of 10 companies, including航中天启, 安闻科技, and映恩生物, have filed for IPO counseling in the past week [1][2] - 航中天启 aims to go public on the A-share market, with a projected revenue exceeding 1 billion yuan in 2024 [2][3] - 安闻科技, led by国投招商, is focused on automotive safety and comfort components, with a registered capital of 360 million yuan [5][6] - 映恩生物, a Hong Kong-listed company with a market value of 27.1 billion HKD, plans to return to the A-share market, despite significant losses projected for 2025 [2][8] Group 2: Company Profiles - 航中天启 specializes in high-speed power line carrier communication chips and has over 40 million modules shipped, with a revenue of over 1 billion yuan [4] - 安闻科技 has developed a one-stop solution for automotive thermal comfort systems and has a strong client base among domestic car manufacturers [6][7] - 映恩生物 focuses on antibody-drug conjugates (ADC) for cancer treatment, with several products in clinical stages and a significant revenue increase projected for 2025 [9][10] - 嘉晨电子, established in 2016, specializes in high-voltage safety systems for the new energy vehicle sector [11][12] - 东源环保 is a leading environmental water service provider in Inner Mongolia, focusing on integrated water environment solutions [13][14] - 精一股份, a high-tech enterprise in office seating design and manufacturing, is facing a situation of increasing revenue but declining profits [15][16] - 深圳中基, which provides automation equipment for lithium battery production, has seen a significant drop in revenue in the first half of 2025 [17][18] - 新远科技, a leader in epoxy resin diluents, is reapplying for IPO after previously withdrawing its application [19][20] - 锦莱化工, a supplier to major oil companies, specializes in high-tech chemical products and has a strong international presence [22][23] - 华诺星空, focusing on security and emergency response technologies, is changing its IPO counseling institution to平安证券 [24][25]

Group 1 - This week, two new stocks will be available for subscription, both from the Sci-Tech Innovation Board [2][4] - Last week, four new stocks debuted in the A-share market, with Dapeng Industrial leading the gains at 1211.11%, marking the highest first-day increase for new stocks this year [2][3] - Dapeng Industrial's revenue for 2022-2024 is projected to be 247 million, 260 million, and 265 million yuan, with net profits of approximately 40.89 million, 48.69 million, and 43.49 million yuan respectively [3] Group 2 - Three companies are undergoing IPO review this week: Yongda Co., Ltd., Meidel, and Haifiman, all from the North Exchange [4][5] - Yongda Co., Ltd. aims to raise 458 million yuan, focusing on pressure vessel development in various sectors, with projected revenues of 696 million, 712 million, and 819 million yuan from 2022 to 2024 [4] - Meidel plans to raise 645 million yuan, with expected revenues of 1.031 billion, 1.009 billion, and 1.138 billion yuan for 2022 to 2024 [5] Group 3 - Haifiman is set to raise 430 million yuan, with projected revenues for 2025 ranging from 232 million to 266 million yuan, and net profits expected to be between 70 million and 85 million yuan [8][9] - Meidel's major client is BYD, accounting for 31.55% of its revenue in the first half of 2025, with sales amounting to approximately 224.52 million yuan [6][7]

Core Viewpoint - Tambor Group Limited has submitted its prospectus to the Hong Kong Stock Exchange, with CICC as the exclusive sponsor, aiming to capitalize on the growing outdoor apparel market in China [1] Financial Performance - Tambor's revenue for the years 2022 to 2024 is projected to be RMB 732.4 million, RMB 1.021 billion, and RMB 1.302 billion respectively, with net profits of RMB 85.8 million, RMB 139.2 million, and RMB 107.3 million [2] - In the first half of 2025, the company achieved revenue of RMB 658 million, representing an 85% year-on-year increase, and a net profit of RMB 35.9 million, up 205.6% [1][2] Market Position - According to ZhiShi Consulting, Tambor is the fourth largest domestic professional outdoor apparel brand in China based on retail sales in 2024 [1] Dividend Policy - Prior to the IPO, the company distributed significant dividends, with a total dividend of RMB 35 million for the year 2022 and RMB 290 million for the first half of 2025 [5] Leadership - Wang Lili, the chairwoman and general manager of the company, has over 30 years of experience in the textile and retail sectors, overseeing strategic initiatives and overall management [3][4]

Core Viewpoint - Jiangsu Yongda Chemical Machinery Co., Ltd. (Yongda Co.) is set to undergo its IPO review on November 26, 2025, with a planned fundraising of 457.81 million yuan, significantly reduced from the initial target of 607.79 million yuan [1][3][5]. Group 1: Company Overview - Yongda Co. was established in August 2009 and specializes in the research, design, manufacturing, sales, and related technical services of pressure vessels in various sectors, including basic chemicals, coal chemicals, refining, petrochemicals, photovoltaics, and pharmaceuticals [3]. - The company plans to issue no more than 46.52 million shares in its IPO [3]. Group 2: Fundraising and Project Details - The IPO proceeds will primarily fund the construction of a heavy chemical equipment production base, with a total investment of 591 million yuan, utilizing 457.81 million yuan from the IPO [4]. - The company has canceled a 50 million yuan supplementary working capital project, indicating a strategic decision to maintain ethical standards after significant cash dividends totaling 203 million yuan from 2021 to 2024 [5]. Group 3: Financial Performance - Yongda Co. has shown revenue growth from 696 million yuan in 2022 to an expected 819 million yuan in 2024, but net profits have fluctuated, with a decrease from 131 million yuan in 2023 to an expected 107 million yuan in 2024, indicating a trend of increasing revenue without corresponding profit growth [7][8]. - For 2025, the company forecasts a revenue decline of approximately 14.56% to 8.46%, with net profits expected to range from 113 million to 130 million yuan, reflecting a potential profit increase despite revenue decline [8][10]. Group 4: Customer Base and Stability - The company has a high customer concentration, with the top five customers accounting for 85.36% to 86.69% of total sales during the reporting period, but these customers have shown instability, with only one customer consistently appearing in the top rankings over the years [11][12]. - The frequent changes in major customers raise concerns about the stability of Yongda Co.'s revenue streams, despite claims of long-term relationships based on product quality and technical expertise [11]. Group 5: Production Capacity and Industry Challenges - Yongda Co. plans to increase its production capacity from 25,000 tons to 55,000 tons per year, despite a significant drop in capacity utilization from 106.64% in 2023 to 83.83% in 2024 [13]. - The company faces challenges in its downstream industries, particularly in chemicals and photovoltaics, which are experiencing low operational rates and overall industry pressure, raising questions about the appropriateness of its expansion strategy [13].

Core Viewpoint - Green Biological, a well-known company in the spice industry, has submitted its third IPO application to the Shenzhen Stock Exchange, which was accepted on November 21. The company has faced challenges in its previous attempts due to issues related to environmental compliance and profit warnings [1]. Group 1: IPO Journey - Green Biological's IPO journey has been tumultuous, with the first application in December 2020 being withdrawn due to failure to disclose environmental penalties and profit warnings. The second attempt in 2023 was also withdrawn after two rounds of inquiries, with the Shenzhen Stock Exchange focusing on environmental compliance and the company's positioning on the Growth Enterprise Market [1]. - The current IPO aims to raise 690 million yuan, with 420 million yuan allocated to a project for producing 6,300 tons of high-end spices, 120 million yuan for factory facility upgrades, 70 million yuan for R&D enhancements, and 80 million yuan for working capital [1]. Group 2: Company Overview - Established in December 1999, Green Biological is recognized as a "specialized, refined, distinctive, and innovative" enterprise in Zhejiang Province and ranks among the top ten companies in China's light industry spice sector. The company has undertaken four national torch plan projects and has been involved in drafting five national standards and 15 industry standards [1]. - The company specializes in the research and production of nearly 40 types of spice products, including turpentine, cedar oil, and fully synthetic series. Its core products are widely used in daily chemical fragrance formulations, covering household cleaning and personal care products [2]. Group 3: Financial Performance - From 2022 to 2024, the company's revenue is projected to grow from 631 million yuan to 961 million yuan, while net profit is expected to rise from 68.14 million yuan to 150 million yuan. The compound annual growth rates for revenue and net profit over the last three years are 23.35% and 48.59%, respectively. In the first half of 2025, revenue and net profit were reported at 548 million yuan and 94.58 million yuan, respectively [2]. - The company maintains a high export ratio, with over 85% of sales coming from international markets, primarily in Europe and North America. The top five customers account for more than 40% of total revenue [2]. Group 4: Shareholding Structure - The shareholding structure of Green Biological is notable, with the 83-year-old founder and chairman, Lu Wencong, holding 27.11% of the shares. His daughter, Lu Wei, who is also a director and deputy general manager, holds 9%, and together they control 36.11% of the shares. Lu Wei's shares were transferred to her from Lu Wencong in June 2025 [3]. - Prior to the IPO, the top ten individual shareholders are all company executives or former employees, with the core management team holding over 57% of the shares. This governance structure raises questions about the independence and decision-making mechanisms within the company [3].

Group 1: Mandu International - Mandu International submitted its prospectus to the Hong Kong Stock Exchange on November 20, aiming for a main board listing, with Huatai International as the sole sponsor [3] - The company launched China's first 5% minoxidil solution in 2001, addressing the consumer medical demand for hair loss treatment, and has since developed various formulations to cater to different genders and scenarios [3] - Mandu's flagship product, the Mandu® series of minoxidil hair loss treatment products, has ranked first in the Chinese hair loss drug market for ten consecutive years, holding approximately 57% and 71% market shares in the hair loss drug and minoxidil drug markets respectively in 2024 [4] - Revenue figures for Mandu International from 2022 to 2024 are projected at 982 million yuan, 1.228 billion yuan, and 1.455 billion yuan, with a compound annual growth rate (CAGR) of 21.7% [4] - Net profit for the same period is expected to be 202 million yuan, 341 million yuan, and 390 million yuan, with net profit margins of 20.5%, 27.8%, and 26.8% respectively [4] Group 2: Haiwei Electronics - Haiwei Electronics began its IPO process, with subscription open until November 25, and plans to list on the Hong Kong Stock Exchange under the stock code "9609" on November 28, 2025 [6] - The company plans to issue 30,831,400 H-shares, with 3,083,200 shares available for public offering in Hong Kong and 27,748,200 shares for international offering, having secured cornerstone investment exceeding 218 million HKD [6] - Haiwei Electronics is the second-largest manufacturer of capacitor films in China, holding a market share of 10.9% based on revenue from capacitor base films in 2024 [6][7] - The capacitor base film market in China is projected to grow at a CAGR of 19.7%, increasing from 46,200 tons in 2019 to 113,400 tons in 2024, with further growth expected to reach 224,100 tons by 2029 [7] - Haiwei Electronics is the only major manufacturer in China with the capability to design and develop its own capacitor base film production lines, offering a range of film thicknesses from 2.7 to 13.8 microns [7][8]